Fig. 7From: Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthmaUncertainty in biomarker cut-offs in subgroups identified by SIDES in the STRATOS 1 all-comers population (full analysis set)*. *Number of bootstrap samples was 500. FeNO, fractional exhaled nitric oxide; SIDES, Subgroup Identification based on Differential Effect SearchBack to article page